{"product_id":"diagnosis-and-management-of-hypertrophic-cardiomyopathy-hardback-9781405117326","title":"Diagnosis and Management of Hypertrophic Cardiomyopathy (Hardback) 9781405117326","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eDiagnosis and Management of Hypertrophic Cardiomyopathy\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eBarry J. Maron (Edited by), BJ Maron (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781405117326, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 27 February 2004\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e524 pages\u003cbr\u003e23.6 x 15.7 x 3.4 cm, 1.075 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003ci\u003eDiagnosis and Management of Hypertrophic Cardiomyopathy\u003c\/i\u003e is a unique, multi-authored compendium of information regarding the complexities of clinical and genetic diagnosis, natural history, and management of hypertrophic cardiomyopathy (HCM)—the most common and important of the genetic cardiovascular diseases—as well as related issues impacting the health of trained athletes.\u003c\/p\u003e \u003cp\u003eEdited by Dr. Barry J. Maron, a world authority on HCM, and with major contributions from all of the international experts in this field, this book provides a single comprehensive source of information concerning HCM. Recent advances in the field are discussed, including the importance of left ventricular outflow tract obstruction, the use of implantable defibrillators for the prevention of sudden death in young people, definition of the genetic basis for HCM and its role in clinical diagnosis and risk stratification, the development of more precise strategies for assessing the level of risk for sudden death among all patients with HCM, and the evolution of invasive interventions for heart failure symptoms, such as surgical management and its alternatives (alcohol septal ablation and dual-chamber pacing).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eKey Features:\u003c\/b\u003e\u003c\/p\u003e \u003cul\u003e \u003cli\u003eContributions from \u003ci\u003eall\u003c\/i\u003e experts in the field, representing diverse viewpoints regarding this heterogeneous disease and related issues in athletes\u003c\/li\u003e \u003cli\u003eInformation to dispel misunderstandings regarding issues associated with HCM and cardiovascular disease in athletes\u003c\/li\u003e \u003cli\u003eThe only comprehensive source of information available on the topic\u003c\/li\u003e \u003c\/ul\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eForeword, ix\u003cbr\u003e\u003ci\u003ePravin M. Shah, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eDedication and Acknowledgments, xi\u003cbr\u003eList of Contributors, xiii\u003c\/p\u003e \u003cp\u003e1 Phenotypic Expression and Clinical Course of Hypertrophic Cardiomyopathy, 1\u003cbr\u003e\u003ci\u003eBarry J. Maron, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Genetic Mutations that Remodel the Heart in Hypertrophic Cardiomyopathy, 37\u003cbr\u003e\u003ci\u003eCarolyn Y. Ho, MD and Christine E. Seidman, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Genetic Basis and Genotype–Phenotype Relationships in Familial Hypertrophic Cardiomyopathy, 67\u003cbr\u003e\u003ci\u003eAlbert A. Hagège, MD, PhD, Ketty Schwartz, PhD, Michel Desnos, MD, and Lucie Carrier, PhD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Historical Perspective, Mechanism, and Clinical Significance of Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy, 81\u003cbr\u003e\u003ci\u003eMartin S. Maron, MD, Iacopo Olivotto, MD, and Barry J. Maron, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Hypertrophic Cardiomyopathy with Latent (Provocable) Obstruction: Pathophysiology and Management, 95\u003cbr\u003e\u003ci\u003eE. Douglas Wigle, MD, Maria Eriksson, MD, PhD, Paul Rakowski, David Focsaneanu, Cairrine Sloggett, RN, Anna Woo, MD, and Harry Rakowski, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy, 105\u003cbr\u003e\u003ci\u003eIacopo Olivotto, MD, Barry J. Maron, MD, and Franco Cecchi, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Other Modes of Disability or Death Including Stroke, and Treatment Strategies, in Hypertrophic Cardiomyopathy, 121\u003cbr\u003e\u003ci\u003eFranco Cecchi, MD, Iacopo Olivotto, MD, and Barry J. Maron, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Disturbed Vascular Control in Hypertrophic Cardiomyopathy: Mechanisms and Clinical Significance, 132\u003cbr\u003e\u003ci\u003eRoss Campbell, BSc, Jayne A. Morris-Thurgood, PhD, and Michael P. Frenneaux, FRCP, FRACP\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Clinical Significance of Diastolic Dysfunction and the Effect of Therapeutic Interventions, 147\u003cbr\u003e\u003ci\u003eSandro Betocchi, MD and Raffaella Lombardi, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Value of Exercise Testing in Assessing Clinical State and Prognosis in Hypertrophic Cardiomyopathy, 158\u003cbr\u003e\u003ci\u003eSanjay Sharma, MRCP, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Pathophysiology and Significance of Myocardial Ischemia in Hypertrophic Cardiomyopathy, 172\u003cbr\u003e\u003ci\u003eRajesh Thaman, MBBS, MRCP, Bhavesh Sachdev, MBBS, MRCP, and Perry M. Elliott, MBBS, MD, MRCP\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Hypertrophic Cardiomyopathy in Japan: Clinical, Morphologic and Genetic Expression, 185\u003cbr\u003e\u003ci\u003eYoshinori Doi, MD, PhD, Hiroaki Kitaoka, MD, Nobuhiko Hitomi, MD, Naohito Yamasaki, MD, Yoshihisa Matsumura, MD, Takashi Furuno, MD, and Barry J. Maron, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Prevalence, Prevention and Treatment of Infective Endocarditis in Hypertrophic Cardiomyopathy, 195\u003cbr\u003e\u003ci\u003ePaolo Spirito, MD, Marco Piccininno, MD, and Camillo Autore, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Pharmacologic Treatment of Symptomatic Hypertrophic Cardiomyopathy, 200\u003cbr\u003e\u003ci\u003eMark V. Sherrid, MD and Ivan Barac, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Obstructive Hypertrophic Cardiomyopathy: Results of Septal Myectomy, 220\u003cbr\u003e\u003ci\u003eJoseph A. Dearani, MD and Gordon K. Danielson, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 United States Perspectives on the Role of Dual-Chamber Pacing in Patients with Hypertrophic Cardiomyopathy, 236\u003cbr\u003e\u003ci\u003ePaul Sorajja, MD, Steve R. Ommen, MD, and Rick A. Nishimura, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Dual-Chamber Pacing for Hypertrophic Obstructive Cardiomyopathy, 246\u003cbr\u003e\u003ci\u003eXavier Jeanrenaud, MD and Lukas Kappenberger, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Alcohol Septal Ablation, 259\u003cbr\u003e\u003ci\u003eHubert Seggewiss, MD, Angelos Rigopoulos, MD, Lothar Faber, MD, and Peer Ziemssen, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Alcohol Septal Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Seven-Year Experience, 279\u003cbr\u003e\u003ci\u003eHorst Kuhn, MD, Thorsten Lawrenz, MD, Frank Lieder, MD, Frank H. Gietzen, MD, Ludger Obergassel, MD, Claudia Strunk-Muller, MD, Berit Stolle, MD, and Christian H. Leuner, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Role of Septal Ablation in a Surgical Center, 297\u003cbr\u003e\u003ci\u003eHarry M. Lever, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Molecular and Clinical Tools for Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy, 307\u003cbr\u003e\u003ci\u003eAsifa Quraishi, MB, MRCP, Mohammad S. Hamid, MB, MRCP, and William J. McKenna, MD, FRCP\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Risk Stratification For Sudden Death in Hypertrophic Cardiomyopathy: Extreme Left Ventricular Hyptertrophy as a New Indicator of Risk, 319\u003cbr\u003e\u003ci\u003ePaolo Spirito, MD and Barry J. Maron, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Implantable Defibrillator for Prevention of Sudden Death in Hypertrophic Cardiomyopathy, 327\u003cbr\u003e\u003ci\u003eBarry J. Maron, MD, Win-Kuang Shen, MD, and Paolo Spirito, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Hypertrophic Cardiomyopathy and Other Causes of Sudden Death in the Trained Athlete: An Electrophysiologist Perspective on the Management of Benign and Not So Benign Arrhythmias, 345\u003cbr\u003e\u003ci\u003eN. A. Mark Estes III, MD, Paul J. Wang, MD, Munther K. Homoud, MD, and Mark S. Link, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 The Athlete's Heart, ECG, and Differential Diagnosis with Hypertrophic Cardiomyopathy and Other Cardiomyopathies, 367\u003cbr\u003e\u003ci\u003eAntonio Pelliccia, MD and Barry J. Maron, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Importance of Congenital Coronary Artery Anomalies, 382\u003cbr\u003e\u003ci\u003eCristina Basso, MD, PhD, Domenico Corrado, MD, and Gaetano Thiene, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Arrhythmogenic Right Ventricular Cardiomyopathy and Hypertrophic Cardiomyopathy: Identification with the Italian Preparticipation Athlete Screening Program, 393\u003cbr\u003e\u003ci\u003eDomenico Corrado, MD, Cristina Basso, MD, PhD, Maurizio Schiavon, MD, and Gaetano Thiene, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Cardiovascular Causes of Sudden Death, Preparticipation Screening, and Criteria for Disqualification in Young Athletes, 404\u003cbr\u003e\u003ci\u003eBarry J. Maron, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Sudden Death Due to Chest Blows (Commotio Cordis), 432\u003cbr\u003e\u003ci\u003eMark S. Link, MD, N. A. Mark Estes III, MD, and Barry J. Maron, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Naturally Occurring Animal Models of Cardiovascular Disease Causing Premature Death, 448\u003cbr\u003e\u003ci\u003ePhilip R. Fox, DVM\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 The Role of the Internet and Patient Support Groups for Those Living with Hypertrophic Cardiomyopathy, 473\u003cbr\u003e\u003ci\u003eLisa Salberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAfterword, 481\u003cbr\u003e\u003ci\u003eRobert Jon Pensack, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex, 487\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Medicine: general issues [\u003ca title=\"See our other books on Medicine: general issues\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Medicine:%20general%20issues%20%5BMB%5D%22\"\u003eMB\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Brand New","offer_id":52437753135384,"sku":"9781405117326","price":109.46,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781405117326.jpg?v=1784938127","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/diagnosis-and-management-of-hypertrophic-cardiomyopathy-hardback-9781405117326","provider":"Freshly Printed Books","version":"1.0","type":"link"}